Total raised
—
Last: Seed 2019-01
Stage
Seed
Founded
2018
Headcount
1-10
HQ
Sector
Health Tech & Life Sciences
About
Glixogen Therapeutics is a biopharmaceutical company developing a treatment to enhance remyelination in neurodegenerative disorders that are driven by damage to the neuron's myelin sheath, such as multiple sclerosis (MS). Glixogen Therapeutics has discovered selective small molecule inhibitors of the transcription factor Gli1, a novel target that facilitates neuronal remyelination towards modifying the outcome of the disease. Glixogen Therapeutics was founded at the FutuRx biotechnology incubator.
Funding history · 1 round · — total
2019-01
Seed
Undisclosed
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Tags
biotechnologybiopharmaceuticalpharma-companiestherapeuticstreatmentsdegenerative-diseasesneurosciencedrug-discovery